79 women aged 50 or older and 50 clinicians were enrolled into this study to compare the treatment decision making process and subsequent patient adherence to bisphosphonates using the Osteoporosis Choice (OC) decision aid and usual care with or without the fracture risk assessment tool (FRAX) for osteopenia or osteoporosis. The results indicated that several decision making process outcomes significantly favoured the Osteoporosis Choice group. However, due to a lack of funding patient enrollment was reduced from initial targets and the trial was not adequately sized to detect differences in treatment adherence between groups. As such, it is recommended that subsequent studies with larger sample sizes that place a larger focus on adherence outcomes are conducted.